Posted by Michael Wonder on 30 Jan 2023
Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor pimicotinib (ABSK021)
30 January 2023 - Abbisko Therapeutics today announced that its CSF-1R inhibitor pimicotinib (ABSK021) has been granted breakthrough therapy designation from the FDA for the treatment of tenosynovial giant cell tumour patients that are not amenable to surgery.
This breakthrough therapy designation approval is based on results from the Phase Ib clinical trial of tenosynovial giant cell tumour cohort for pimicotinib.
